Jiangsu Nhwa Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Jiangsu Nhwa Pharmaceutical Co Ltd cash flow-to-debt ratio. Jiangsu Nhwa Pharmaceutical Co Ltd (002262) has a Cash Flow-to-Debt Ratio of 0.42x as of September 2025, meaning its operating cash flow of CN¥425.83 Million could theoretically repay 0% of its total liabilities (CN¥1.00 Billion) in one year. Check 002262 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Jiangsu Nhwa Pharmaceutical Co Ltd (2005–2025)
Cash flow-to-debt ratio of Jiangsu Nhwa Pharmaceutical Co Ltd from 2005 to 2025. Historical debt coverage capacity for Jiangsu Nhwa Pharmaceutical Co Ltd across 21 annual periods. Check Jiangsu Nhwa Pharmaceutical Co Ltd (002262) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Jiangsu Nhwa Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (2005–2025)
Jiangsu Nhwa Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 2005 to 2025. Year-by-year debt coverage analysis for Jiangsu Nhwa Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see 002262 cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.90x | CN¥1.08 Billion | CN¥1.20 Billion | ▲ +14.9% |
| 2024 | 0.79x | CN¥916.13 Million | CN¥1.17 Billion | ▼ -28.5% |
| 2023 | 1.10x | CN¥1.01 Billion | CN¥918.09 Million | ▲ +14.5% |
| 2022 | 0.96x | CN¥861.02 Million | CN¥897.43 Million | ▲ +8.6% |
| 2021 | 0.88x | CN¥701.12 Million | CN¥793.45 Million | ▼ -50.0% |
| 2020 | 1.77x | CN¥1.25 Billion | CN¥706.67 Million | ▲ +244.5% |
| 2019 | 0.51x | CN¥305.97 Million | CN¥596.68 Million | ▲ +36.2% |
| 2018 | 0.38x | CN¥404.52 Million | CN¥1.07 Billion | ▼ -30.1% |
| 2017 | 0.54x | CN¥452.35 Million | CN¥840.24 Million | ▲ +65.3% |
| 2016 | 0.33x | CN¥277.14 Million | CN¥850.97 Million | ▲ +15.4% |
| 2015 | 0.28x | CN¥204.24 Million | CN¥723.60 Million | ▲ +52.1% |
| 2014 | 0.19x | CN¥160.24 Million | CN¥863.61 Million | ▼ -30.3% |
| 2013 | 0.27x | CN¥194.33 Million | CN¥730.13 Million | ▲ +14.4% |
| 2012 | 0.23x | CN¥154.16 Million | CN¥662.41 Million | ▲ +54.3% |
| 2011 | 0.15x | CN¥81.08 Million | CN¥537.59 Million | ▲ +20.0% |
| 2010 | 0.13x | CN¥61.79 Million | CN¥491.74 Million | ▼ -21.1% |
| 2009 | 0.16x | CN¥61.27 Million | CN¥384.68 Million | ▲ +32.1% |
| 2008 | 0.12x | CN¥46.50 Million | CN¥385.66 Million | ▲ +10.4% |
| 2007 | 0.11x | CN¥48.55 Million | CN¥444.39 Million | ▲ +34.5% |
| 2006 | 0.08x | CN¥30.99 Million | CN¥381.63 Million | ▲ +228.0% |
| 2005 | 0.02x | CN¥8.84 Million | CN¥357.12 Million | — |